mRNA-In® Transfection Reagent was developed by members of the scientific team that invented Lipofectamine® and Lipofectamine® 2000 and specifically formulated for in vitro mRNA delivery. Maximum RNA delivery is achieved with mRNA-In® using lower amounts of mRNA than other reagents, reducing experimental costs and significantly lowering toxicity. Across a wide range of cell types, mRNA-In™ has shown to produce exceptionally high transfection efficiency while maintaining optimal cell health and viability.
Requires low amounts of RNA - reduce cost and potential off-target toxicity effects with low amounts of RNA requirements.
Transfects a variety of cell lines with as little as 2 pg/cell of mRNA
High expression, low toxicity - achieve high mRNA efficiency while maintaining optimal cell health for uncompromised experiment results.
Robust, versatile performance - produce efficient transfection across a wide range of cell type, including stem cells and primary cells.
mRNA-In® Transfection Reagent is ideal for mRNA delivery for various applications, such as protein expression and iPSC-reprogramming. Data below also shows mRNA-In® significantly outperforms competitor reagents, typically achieving 90% or greater transfection efficiency across a wide range of cell types.
Making the Optimal Messenger RNA for Gene Therapy Applications.pdf [ TriLink]
A Reproducible, Efficient and User-friendly RNA Reprogramming System.pdf [ESIBio]
Data below show commonly used cell types transfected with mRNA-In® Transfection Reagent using various amounts of mRNA. Cells were plated in 24-well plates to give 60-70% confluence the day of transfection. GFP-mRNA containing 5-methlycytosine and psuedouridine were complexed with various amounts of mRNA-In® in a total of 50µl of OptiMEM®. For each experiment mRNA /mRNA-In™ complexes were added to cells, mixed, and incubated at 37ºC in 5% CO2. Cells were observed 24 hours following transfection.
Below, SH-SY5Y (neuroblastoma cells), HDF (human dermal fibroblasts), HUVEC (human umbilical vein endothelial cells), HeLa and adipose-derived Mesenchymal Stem Cells (MSCs) were transfected with mRNA-In™ or MessengerMAX™ (Life Technologies) using low amounts of mRNA (100ng). Cells were plated in 24-well plates to give 60-70% confluence the day of transfection. GFP-mRNA containing 5-methlycytosine and psuedouridine were complexed with the various amounts of mRNA-In® (see chart legends). RNA/reagent complexes were added to the cells, mixed, and incubated at 37ºC in 5% CO2 overnight. Cells were analyzed by a fluorescence plate reader and microscopy 24 hours post-transfection. Error bars represent the standard deviation of triplicate wells. The data below shows mRNA-In™ provides significantly higher transfection efficiency than the competitor reagent.
技术支持：易动力网络
